Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Q cycle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Q cycle. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-003226-42 Sponsor Protocol Number: 91550 Start Date*: 2008-12-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, active-controlled, parallel group, 2-arm study to investigate the effect of estradiol valerate/dienogest compared to Microgynon on hormone withdrawal associ...
    Medical condition: Hormone withdrawal associated symptoms of headache and pelvic pain suffered by patients receiving LNG containing oral contraception.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030970 Oral contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) DE (Completed) ES (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003983-30 Sponsor Protocol Number: CPH-303-201400 Start Date*: 2019-05-22
    Sponsor Name:Croma-Pharma GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study.
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002675-17 Sponsor Protocol Number: NCT-2017-0545 Start Date*: 2019-12-20
    Sponsor Name:Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital
    Full Title: Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD
    Medical condition: Relapsed/Refractory AML with FLT3-ITD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003841-86 Sponsor Protocol Number: Y-52-52120-214 Start Date*: 2015-04-30
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabe...
    Medical condition: Moderate to severe Glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002164-16 Sponsor Protocol Number: CPH-301-201030 Start Date*: 2016-04-11
    Sponsor Name:CROMA-PHARMA GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002109-73 Sponsor Protocol Number: NiCCC2013 Start Date*: 2013-11-14
    Sponsor Name:Greater Glasgow Health Board
    Full Title: A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium
    Medical condition: Recurrent clear cell carcinoma of the ovary or endometrium
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009252 Clear cell endometrial carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-005132-26 Sponsor Protocol Number: CA209-025 Start Date*: 2012-09-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther...
    Medical condition: Advanced or metastatic (medically or surgically unresectable) clear-cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) HU (Completed) CZ (Completed) DK (Completed) ES (Completed) NO (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004034-29 Sponsor Protocol Number: A206T-G01-001 Start Date*: 2018-12-19
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi...
    Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001876-12 Sponsor Protocol Number: LPRI-424/301 Start Date*: 2019-12-16
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicentre, uncontrolled trial on the contraceptive efficacy, safety, tolerability and pharmacokinetics of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during 13 cycles
    Medical condition: Oral contraception for females aged 18-45
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    21.1 10042613 - Surgical and medical procedures 10030970 Oral contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) LT (Completed) PT (Not Authorised) ES (Completed) BG (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000893-32 Sponsor Protocol Number: 008171BLT Start Date*: 2014-02-17
    Sponsor Name:Queen Mary University of London
    Full Title: Squamous cell carcinoma prevention in organ transplant recipients using topical treatments: a feasibility study (SPOT)
    Medical condition: Actinic keratosis (and cutaneous squamous cell carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001877-97 Sponsor Protocol Number: LPRI-424/302 Start Date*: 2020-02-19
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicentre, double-blind, double-dummy, randomised trial on the contraceptive efficacy, tolerability and safety of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during nine cycles in com...
    Medical condition: Oral contraception for females aged 18-45
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    21.1 10042613 - Surgical and medical procedures 10030970 Oral contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) CZ (Completed) SK (Completed) HU (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022648-19 Sponsor Protocol Number: P05898 Start Date*: 2011-11-16
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A 26-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed episodes Associated With Bipolar I Disorder
    Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000822-37 Sponsor Protocol Number: UM203 Start Date*: 2017-10-30
    Sponsor Name:Asarina Pharma
    Full Title: A phase II, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study investigating efficacy and safety of Sepranolone (UC1010) in patients with PMDD
    Medical condition: Premenstrual dysphoric disorder (PMDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002999-34 Sponsor Protocol Number: Y-79-52120-126 Start Date*: 2007-12-04
    Sponsor Name:Ipsen Limited
    Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ...
    Medical condition: Idiopathic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003084-61 Sponsor Protocol Number: CLEE011A2301 Start Date*: 2014-01-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast ...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) NL (Completed) HU (Completed) FI (Completed) IE (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001040-62 Sponsor Protocol Number: GBG78/BIG1-13 Start Date*: 2013-11-14
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r...
    Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    21.1 100000004865 10025025 Lumpectomy (breast cancer) LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-001673-14 Sponsor Protocol Number: CCTL019A2205B Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
    Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000588-42 Sponsor Protocol Number: APN311-304 Start Date*: 2015-03-16
    Sponsor Name:Medical University Greifswald
    Full Title: PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA
    Medical condition: PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006198-25 Sponsor Protocol Number: HE7/12 Start Date*: 2012-10-24
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A Phase II, single-arm clinical trial of administration of cisplatin and 5-fluorouracil with afatinib as first-line therapy in patients with inoperable gastric or gastroesophageal junction cancer
    Medical condition: Inoperable gastric and gastroesophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001356-37 Sponsor Protocol Number: NSGO-CC-0304 Start Date*: 2004-09-10
    Sponsor Name:Nordic Society for Gynecological Cancer
    Full Title: Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer
    Medical condition: Metastatic or recurrent cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:23:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA